Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.

被引：0
|
作者：
Ravandi, Farhad
Carraway, Hetty E.
Taningco, Lilia
Laille, Eric
Gong, Jing
Prebet, Thomas
De Menezes, Daniel Lopes
Wei, Andrew H.
机构：
[1] Univ Texas MD derson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Taussig Canc Inst, Cleveland Clin, Leukemia Program, Cleveland, OH USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Peter MacCallum Canc Ctr, Melbourne, VIC, Australia
[5] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7068
引用
收藏
页数：1
相关论文
共 50 条
  • [1] OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
    Ravandi, Farhad
    Carraway, Hetty E.
    Taningco, Lilia
    Dilley, Kimberley
    Laille, Eric
    Gong, Jing
    de Menezes, Daniel Lopes
    Wei, Andrew H.
    BLOOD, 2021, 138
  • [2] Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
    Garciaz, Sylvain
    Hospital, Marie-Anne
    Alary, Anne-Sophie
    Saillard, Colombe
    Hicheri, Yosr
    Mohty, Bilal
    Rey, Jerome
    D'Incan, Evelyne
    Charbonnier, Aude
    Villetard, Ferdinand
    Maisano, Valerio
    Lombardi, Laura
    Ittel, Antoine
    Mozziconacci, Marie-Joelle
    Gelsi-Boyer, Veronique
    Vey, Norbert
    CANCERS, 2022, 14 (08)
  • [3] Phase 1b OMNIVERSE trial: Safety and tolerability of oral azacitidine (Oral-AZA) in combination with venetoclax (VEN) for treatment of acute myeloid leukemia
    Fleming, Shaun
    Roboz, Gail J.
    Fathi, Amir Tahmasb
    Zhang, Tian Yi
    Wei, Andrew
    Carraway, Hetty E.
    Holes, Leanne
    Petrlik, Erica
    Prebet, Thomas
    De Menezes, Daniel Lopes
    Bluemmert, Iryna
    Sun, Hao
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
    Jonas, Brian A.
    Hou, Jing-Zhou
    Roboz, Gail J.
    Alvares, Caroline L.
    Jeyakumar, Deepa
    Edwards, John R.
    Erba, Harry P.
    Kelly, Richard J.
    Roellig, Christoph
    Fiedler, Walter
    Brackman, Deanna
    Siddani, Satya R.
    Chyla, Brenda
    Hilger-Rolfe, Jacqueline
    Watts, Justin M.
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 743 - 752
  • [5] Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study
    Perl, Alexander E.
    Daver, Naval G.
    Pratz, Keith W.
    Maly, Joseph
    Hong, Wan-Jen
    Bahceci, Erkut
    Tong, Bo
    Tian, Tian
    Dilley, Kimberley
    BLOOD, 2019, 134
  • [6] Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
    Maximilian Fleischmann
    Sebastian Scholl
    Jochen J. Frietsch
    Inken Hilgendorf
    Karin Schrenk
    Jakob Hammersen
    Florian Prims
    Christian Thiede
    Andreas Hochhaus
    Ulf Schnetzke
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 3191 - 3202
  • [7] Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
    Fleischmann, Maximilian
    Scholl, Sebastian
    Frietsch, Jochen J.
    Hilgendorf, Inken
    Schrenk, Karin
    Hammersen, Jakob
    Prims, Florian
    Thiede, Christian
    Hochhaus, Andreas
    Schnetzke, Ulf
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (11) : 3191 - 3202
  • [8] Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia
    Lane, Andrew A.
    Garcia, Jacqueline S.
    Raulston, Evangeline G.
    Garzon, Jada L.
    Galinsky, Ilene
    Baxter, Emilie W.
    Leonard, Rebecca
    Deangelo, Daniel J.
    Luskin, Marlise R.
    Reilly, Christopher R.
    Stahl, Maximilian
    Stone, Richard M.
    Vedula, Rahul S.
    Wadleigh, Martha M.
    Winer, Eric S.
    Mughal, Tariq
    Brooks, Christopher
    V. Gupta, Ira
    Stevenson, Kristen E.
    Neuberg, Donna S.
    Ren, Siyang
    Keating, Julia
    Konopleva, Marina
    Sten, Anthony
    Pemmaraju, Naveen
    BLOOD ADVANCES, 2024, 8 (03) : 591 - 602
  • [9] Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia
    Zhong, Xushu
    Wang, Jia
    Dai, Yang
    Huang, Xiaoou
    Liu, Jiazhuo
    Xiang, Bing
    Ma, Hongbing
    HEMATOLOGY, 2024, 29 (01)
  • [10] The propriety of upgrading responses to venetoclax plus azacitidine in newly diagnosed patients with acute myeloid leukemia
    Abbott, Diana
    Cherry, Evan
    Amaya, Maria
    McMahon, Christine
    Schwartz, Marc
    Winters, Amanda
    Schowinsky, Jeffrey
    Jordan, Craig T.
    Smith, Clayton
    Gutman, Jonathan A.
    Pollyea, Daniel A.
    LEUKEMIA & LYMPHOMA, 2021, 62 (06) : 1466 - 1473
12345